Industry
Biotechnology
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Loading...
Open
5.29
Mkt cap
217M
Volume
780
High
5.29
P/E Ratio
-2.47
52-wk high
12.70
Low
5.29
Div yield
N/A
52-wk low
3.32
Portfolio Pulse from Benzinga Newsdesk
November 01, 2024 | 12:37 pm
Portfolio Pulse from Benzinga Insights
November 01, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Insights
November 01, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 8:05 pm
Portfolio Pulse from Benzinga Newsdesk
October 25, 2024 | 6:25 am
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 6:20 am
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 21, 2024 | 12:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.